Sandbox: sadaf: Difference between revisions

Revision as of 20:02, 10 September 2018

Differentiating Pancytopenia from Other Diseases

There are no other mimickers of pancytopenia, as the diagnosis can be unequivocally established by laboratory testing (complete blood count).

Category	Condition	Etiology	Mechanism			Congenital	Acquried	Clinical manifestations									Para−clinical findings								Gold standard	Associated findings
								Demography	History	Symptoms			Signs				Para−clinical findings
										Symptoms			Signs				Lab Findings
										Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other	CBC			PBS	Bone marrow exam	PT	PTT	UA
			Bone marrow infiltration	Bone marrow failure	Destruction/ sequestration/ redistribution					Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA
Hematologic disorders	Myelodysplastic syndrome	Bone marrow infiltration Ineffective hematopoiesis	+	+	−	±	+	Elderly	Exposure to Chemotherapy Radiation therapy Tobacco smoke	Petechiae Purpura Diffuse erythematous rash	+	+	Nl	+	+	Shortness of breath Fatigue Pallor	↓	↓	↓	Ovalomacrocytosis Basophilic stippling Howell-Jolly body Dysplastic neutrophils	Impaired myeloid maturation Dyserythropoiesis Dysgranulopoiesis Dysmegakaryocytopoiesis Hypercellular bone marrow Fibrosis	Nl	Nl	Nl	Bone marrow examination + clinical manifestation	Might transformed to acute leukemia
	Malignancies such as: Acute leukemia Chronic leukemia Multiple myeloma Metastatic cancer	Bone marrow infiltration Ineffective hematopoiesis Immune mediated	+	+	+	±	±	Any, more in adults	Exposure to chemicals Radiation Pre-existent blood disorders	Petechiae	+	+	Nl	+	−	Weakness	↓	↓	↓	Pancytopenia	Blast cells	↑	↑	Hemoglobinuria	Bone marrow examination	Tumor lysis syndrome Infection CNS involvement DIC
	Myelofibrosis^[1]	Bone marrow infiltration	+	+	−	+	+	Average 60 years old	Exposure to chemicals Radiation Pre-existent blood disorders	Pallor Major weight loss	+	+	Nl	+	-	Weakness Fatigue Shortness of breath Headache	↓	↓	↓	Pancytopenia	Pancytopenia Hypercellular bone marrow Fibrosis	↑	↑	Hemoglobinuria	Bone marrow examination	Arrhythmia Infection Seizure May progress to malignancy
	Fanconi anemia
	Condition	Etiology	Bone marrow infiltration	Bone marrow failure	Destruction/ sequestration/ redistribution	Congenital	Acquried	Demography	History	Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Gold standard	Associated findings
	Aplastic anemia^[2]	Unknown	−	+	−	±	±	Biphasic (the young and the elderly)	Exposure to radiation, drugs and chemicals, pregnancy, PNH and viral or autoimmune causes	Pallor	−	+	Nl	−	−	Shortness of breath Fatigue Pallor	↓	↓	↓	Large RBCs Low platelets and granulocytes	Hypocellular bone marrow replacement of bone marrow by fat	↑	↑	Nl	Bone marrow examination + laboratory findings	Fanconi Anemia Dyskeratosis congenita Schwachman-Diamond syndrome Preleukemia
	Paroxysmal nocturnal hemoglobinuria^[3]	Deficiency of complement regulatory proteins Mutations	+	+	−	−	+	Any age (usually younger adults)	Sudden nocturnal hemoglobinuria with partial clearing during the day	Normal	−	−	Nl	−	−	Thrombosis Smooth muscle dystonia	↓/Nl	↓	↓/Nl	Pancytopenia	Cellular marrow Erythroid hyperplasia dyserythropoiesis Hypocellular marrow in certain stages of the disease	Nl	Nl	Hemoglobinuria	Flow cytometry	Chronic renal failure Pulmonary hypertension Aplastic anemia
	Disseminated intravascular coagulation	Consumption
	Dyskeratosis congenital/telomere biology disorders
	Shwachman-Diamond syndrome					+
Immunology/ Rheumatology	Condition	Etiology	Bone marrow infiltration	Bone marrow failure	Destruction/ sequestration/ redistribution	Congenital	Acquried	Demography	History	Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Gold standard	Associated findings
	SLE
	Felty syndrome
	Wiskott Aldrich syndrome					+
	GATA2 deficiency					+
	Hemophagocytic lymphohistiocytosis					+
GI disorders	Portal hypertension/cirrhosis	Splenomegally
GI disorders	Storage diseases (eg, Gaucher)	Splenomegaly Bone marrow infiltration	+		+
Infections	Condition	Etiology	Bone marrow infiltration	Bone marrow failure	Destruction/ sequestration/ redistribution	Congenital	Acquried	Demography	History	Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Gold standard	Associated findings
	Sepsis	Bone marrow infiltration
	Viral infection such as HIV, hepatitis, Epstein-Barr virus	Marrow suppression Splenomegaly		+	+
Nutritional	Megaloblastic anemia	Ineffective hematopoiesis		+
	Excessive alcohol	Ineffective hematopoiesis
	Other nutritional deficiency such as copper deficiency, zinc toxicity	Ineffective hematopoiesis
	Malnutrition	Ineffective hematopoiesis
Medications	Medications such as: Cytotoxic drugs Idiosyncratic reactions to medications	Immune destruction		+
Category	Condition	Etiology	Bone marrow infiltration	Bone marrow failure	Destruction/ sequestration/ redistribution	Congenital	Acquried	Demography	History	Appearance	Fever	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Gold standard	Associated findings

↑ Bae, E.; Park, C.-J.; Cho, Y.-U.; Seo, E.-J.; Chi, H.-S.; Jang, S.; Lee, K.-H.; Lee, J.-H.; Lee, J.-H.; Suh, J.-J.; Im, H.-J. (2013). "Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis". International Journal of Laboratory Hematology. 35 (6): 629–636. doi:10.1111/ijlh.12101. ISSN 1751-5521.
↑ Townsley, Danielle M.; Desmond, Ronan; Dunbar, Cynthia E.; Young, Neal S. (2013). "Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes". International Journal of Hematology. 98 (1): 48–55. doi:10.1007/s12185-013-1352-6. ISSN 0925-5710.
↑ Brodsky RA (2014). "Paroxysmal nocturnal hemoglobinuria". Blood. 124 (18): 2804–11. doi:10.1182/blood-2014-02-522128. PMC 4215311. PMID 25237200.

[BaePark2013-1] Bae, E.; Park, C.-J.; Cho, Y.-U.; Seo, E.-J.; Chi, H.-S.; Jang, S.; Lee, K.-H.; Lee, J.-H.; Lee, J.-H.; Suh, J.-J.; Im, H.-J. (2013). "Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis". International Journal of Laboratory Hematology. 35 (6): 629–636. doi:10.1111/ijlh.12101. ISSN 1751-5521.

[TownsleyDesmond20132-2] Townsley, Danielle M.; Desmond, Ronan; Dunbar, Cynthia E.; Young, Neal S. (2013). "Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes". International Journal of Hematology. 98 (1): 48–55. doi:10.1007/s12185-013-1352-6. ISSN 0925-5710.

[pmid25237200-3] Brodsky RA (2014). "Paroxysmal nocturnal hemoglobinuria". Blood. 124 (18): 2804–11. doi:10.1182/blood-2014-02-522128. PMC 4215311. PMID 25237200.

[1]

[2]

[3]

@@ Line 10: / Line 10: @@
 ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
 ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
-! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
+! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
 ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
 ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
@@ Line 20: / Line 20: @@
 |-
 ! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
-! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
 |-
 ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
@@ Line 46: / Line 45: @@
 |-
 ! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hematologic disorders
-! align="center" style="background:#DCDCDC;" |[[Myelodysplastic syndrome (patient information)|Myelodysplastic syndrome]]<ref name="NatelsonPyatt2013">{{cite journal|last1=Natelson|first1=Ethan A.|last2=Pyatt|first2=David|title=Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog|journal=Advances in Hematology|volume=2013|year=2013|pages=1–11|issn=1687-9104|doi=10.1155/2013/309637}}</ref>
+! align="center" style="background:#DCDCDC;" |[[Myelodysplastic syndrome (patient information)|Myelodysplastic syndrome]]
 | align="left" style="background:#F5F5F5;" |
 * [[Bone marrow]] infiltration
@@ Line 52: / Line 51: @@
 | align="center" style="background:#F5F5F5;" | +
 | align="center" style="background:#F5F5F5;" | +
-| align="center" style="background:#F5F5F5;" | -
+| align="center" style="background:#F5F5F5;" |−
 | align="center" style="background:#F5F5F5;" | ±
 | align="center" style="background:#F5F5F5;" | +
@@ Line 91: / Line 90: @@
 | align="center" style="background:#F5F5F5;" |Nl
 | align="center" style="background:#F5F5F5;" |Nl
-| align="center" style="background:#F5F5F5;" |NA
 | align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation
 | align="center" style="background:#F5F5F5;" |
 *Might transformed to [[acute leukemia]]
 |-
-! align="left" style="background:#DCDCDC;" |Malignancies such as:<ref name="pmid24088751">{{cite journal |vauthors=Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A |title=Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia |journal=Intern. Med. |volume=52 |issue=19 |pages=2193–201 |date=2013 |pmid=24088751 |doi= |url=}}</ref><ref name="OshimaYuji2013">{{cite journal|last1=Oshima|first1=Yasuo|last2=Yuji|first2=Koichiro|last3=Tanimoto|first3=Tetsuya|last4=Hinomura|first4=Yasushi|last5=Tojo|first5=Arinobu|title=Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia|journal=Internal Medicine|volume=52|issue=19|year=2013|pages=2193–2201|issn=0918-2918|doi=10.2169/internalmedicine.52.0324}}</ref>
+! align="left" style="background:#DCDCDC;" |Malignancies such as:
 * [[Acute leukemia]]
 * [[Chronic leukemia]]
@@ Line 121: / Line 119: @@
 | align="center" style="background:#F5F5F5;" + |Nl
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + |
 *[[Muscle weakness|Weakness]]
@@ Line 136: / Line 134: @@
 | align="center" style="background:#F5F5F5;" + |
 *[[Hemoglobinuria]]
-| align="center" style="background:#F5F5F5;" + |NA
 | align="center" style="background:#F5F5F5;" + |Bone marrow examination
 | align="center" style="background:#F5F5F5;" + |
@@ Line 144: / Line 141: @@
 *[[Disseminated intravascular coagulation|DIC]]
 |-
-! align="center" style="background:#DCDCDC;" |[[Myelofibrosis]]
+! align="center" style="background:#DCDCDC;" |[[Myelofibrosis]]<ref name="BaePark2013">{{cite journal|last1=Bae|first1=E.|last2=Park|first2=C.-J.|last3=Cho|first3=Y.-U.|last4=Seo|first4=E.-J.|last5=Chi|first5=H.-S.|last6=Jang|first6=S.|last7=Lee|first7=K.-H.|last8=Lee|first8=J.-H.|last9=Lee|first9=J.-H.|last10=Suh|first10=J.-J.|last11=Im|first11=H.-J.|title=Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis|journal=International Journal of Laboratory Hematology|volume=35|issue=6|year=2013|pages=629–636|issn=17515521|doi=10.1111/ijlh.12101}}</ref>
 | align="left" style="background:#F5F5F5;" + |
 * Bone marrow infiltration
 | align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |Average 60 years old
 | align="center" style="background:#F5F5F5;" + |
+*Exposure to chemicals
+*[[Radiation therapy|Radiation]]
+*Pre-existent blood disorders
 | align="center" style="background:#F5F5F5;" + |
 * [[Pallor]]
@@ Line 181: / Line 181: @@
 | align="center" style="background:#F5F5F5;" + |
 *[[Hemoglobinuria]]
-| align="center" style="background:#F5F5F5;" + |NA
 | align="center" style="background:#F5F5F5;" + |Bone marrow examination
 | align="center" style="background:#F5F5F5;" + |
@@ Line 190: / Line 189: @@
 |-
 ! align="center" style="background:#DCDCDC;" |[[Fanconi anemia]]
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 243: / Line 241: @@
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
 |-
-! align="center" style="background:#DCDCDC;" |[[Aplastic anemia]]
+! align="center" style="background:#DCDCDC;" |[[Aplastic anemia]]<ref name="TownsleyDesmond20132">{{cite journal|last1=Townsley|first1=Danielle M.|last2=Desmond|first2=Ronan|last3=Dunbar|first3=Cynthia E.|last4=Young|first4=Neal S.|title=Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes|journal=International Journal of Hematology|volume=98|issue=1|year=2013|pages=48–55|issn=0925-5710|doi=10.1007/s12185-013-1352-6}}</ref>
-| align="center" style="background:#F5F5F5;" + |
-* Immune destruction
 | align="center" style="background:#F5F5F5;" + |
+*Unknown
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |±
+| align="center" style="background:#F5F5F5;" + |±
+| align="center" style="background:#F5F5F5;" + |Biphasic (the young and the elderly)
 | align="center" style="background:#F5F5F5;" + |
+* Exposure to [[Radiation (medicine)|radiation]], drugs and chemicals, [[pregnancy]], [[Paroxysmal nocturnal hemoglobinuria|PNH]] and viral or [[Autoimmune disease|autoimmune]] causes
 | align="center" style="background:#F5F5F5;" + |
+* [[Pallor]]
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + |
+*[[Shortness of breath]]
+*[[Fatigue]]
+*[[Pallor]]
+| align="center" style="background:#F5F5F5;" + |↓
+| align="center" style="background:#F5F5F5;" + |↓
+| align="center" style="background:#F5F5F5;" + |↓
 | align="center" style="background:#F5F5F5;" + |
+*Large [[Red blood cell|RBCs]]
+*Low [[Platelet|platelets]] and [[Granulocyte|granulocytes]]
 | align="center" style="background:#F5F5F5;" + |
+*Hypocellular [[bone marrow]]
+*replacement of [[bone marrow]] by [[fat]]
+| align="center" style="background:#F5F5F5;" + |↑
+| align="center" style="background:#F5F5F5;" + |↑
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] +
+laboratory findings
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+*[[Fanconi anemia|Fanconi Anemia]]
-| align="center" style="background:#F5F5F5;" + |
+*[[Dyskeratosis congenita]]
-| align="center" style="background:#F5F5F5;" + |
+*[[Shwachman-Diamond syndrome|Schwachman-Diamond syndrome]]
-| align="center" style="background:#F5F5F5;" + |
+*[[Preleukemia]]
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 |-
-! align="center" style="background:#DCDCDC;" |[[Paroxysmal nocturnal hemoglobinuria]]
+! align="center" style="background:#DCDCDC;" |[[Paroxysmal nocturnal hemoglobinuria]]<ref name="pmid25237200">{{cite journal| author=Brodsky RA| title=Paroxysmal nocturnal hemoglobinuria. | journal=Blood | year= 2014 | volume= 124 | issue= 18 | pages= 2804-11 | pmid=25237200 | doi=10.1182/blood-2014-02-522128 | pmc=4215311 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25237200  }}</ref>
-| align="center" style="background:#F5F5F5;" + |Immune destruction
 | align="center" style="background:#F5F5F5;" + |
+*Deficiency of [[complement]] regulatory proteins
+*Mutations
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + |Any age
+(usually younger adults)
 | align="center" style="background:#F5F5F5;" + |
+*Sudden [[nocturnal]] [[hemoglobinuria]] with partial clearing during the day
 | align="center" style="background:#F5F5F5;" + |
+* Normal
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + |−
+| align="center" style="background:#F5F5F5;" + |−
 | align="center" style="background:#F5F5F5;" + |
+*[[Thrombosis]]
+*Smooth muscle [[dystonia]]
+| align="center" style="background:#F5F5F5;" + |↓/Nl
+| align="center" style="background:#F5F5F5;" + |↓
+| align="center" style="background:#F5F5F5;" + |↓/Nl
 | align="center" style="background:#F5F5F5;" + |
+*[[Pancytopenia]]
 | align="center" style="background:#F5F5F5;" + |
+*Cellular [[Bone marrow|marrow]]
+*[[Erythroid]] [[hyperplasia]]
+*[[dyserythropoiesis]]
+*Hypocellular marrow in certain stages of the disease
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + |Nl
 | align="center" style="background:#F5F5F5;" + |
+*[[Hemoglobinuria]]
+| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+*[[Chronic renal failure]]
-| align="center" style="background:#F5F5F5;" + |
+*[[Pulmonary hypertension]]
-| align="center" style="background:#F5F5F5;" + |
+*[[Aplastic anemia]]
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 |-
 ! align="center" style="background:#DCDCDC;" |[[Disseminated intravascular coagulation]]
 | align="center" style="background:#F5F5F5;" + |Consumption
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 333: / Line 359: @@
 |-
 ! align="center" style="background:#DCDCDC;" |Dyskeratosis congenital/telomere biology disorders
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 366: / Line 391: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 416: / Line 440: @@
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
 |-
 ! align="center" style="background:#DCDCDC;" |[[SLE]]
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 449: / Line 471: @@
 |-
 ! align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 482: / Line 503: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 510: / Line 530: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 538: / Line 557: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 564: / Line 582: @@
 | align="left" style="background:#F5F5F5;" + |
 * Splenomegally
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 597: / Line 614: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 647: / Line 663: @@
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
@@ Line 654: / Line 669: @@
 | align="left" style="background:#F5F5F5;" + |
 * Bone marrow infiltration
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 687: / Line 701: @@
 | align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 716: / Line 729: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 743: / Line 755: @@
 | align="left" style="background:#F5F5F5;" + |
 * Ineffective hematopoiesis
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 772: / Line 783: @@
 | align="left" style="background:#F5F5F5;" + |
 * Ineffective hematopoiesis
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 801: / Line 811: @@
 | align="left" style="background:#F5F5F5;" + |
 * Ineffective hematopoiesis
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 835: / Line 844: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 886: / Line 894: @@
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
 |}
 <references />

Sandbox: sadaf: Difference between revisions

Revision as of 20:02, 10 September 2018

Differentiating Pancytopenia from Other Diseases

Navigation menu